Rituximab or a second anti-tumor necrosis factor for rheumatoid arthritis patients who have failed their first antitumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register

収録刊行物

• Arthritis Care Res

  Arthritis Care Res 64 (8), 1108-1115, 2012